Oryzon Genomics S.A (ORYZF PINK) stock market data APIs
$3.2491
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Oryzon Genomics S.A Financial Data Overview
Price chart is built with
Anychart
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Prev. Close
3.2491
Open
3.2491
High
3.2491
Low
3.2491
52 wk Range
1.565-3.2827
Market Cap
258 M
Shares Outstanding
77 513 K
Revenue
7 471 K
EPS
0.0015
Beta
0.427
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oryzon Genomics S.A data using free add-ons & libraries
Get Oryzon Genomics S.A Fundamental Data
Oryzon Genomics S.A Fundamental data includes:
- Net Revenue: 7 471 K
- EBITDA: -4 915 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oryzon Genomics S.A News
New
European Growth Stocks With Significant Insider Ownership
As the European market experiences a modest upswing, with the pan-European STOXX Europe 600 Index rising by 1.40% amid hopes for lower U.S. borrowing costs, investors are keenly observing growth oppor...
High Growth Tech Stocks in Europe Featuring Three Prominent Companies
The European market has recently experienced a positive shift, with the pan-European STOXX Europe 600 Index climbing 1.40% amid optimism surrounding potential U.S. rate cuts and a rise in business act...
High Growth Tech Stocks in Europe to Watch for Potential Expansion
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt furt...
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
Oryzon Genomics, S.A. Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Toplin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
